Group 1 - The core point of the article is that Tongrentang Medical Investment Co., Ltd. has submitted its third listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor. If successful, it will become the fourth listed platform under the Tongrentang Group [1] Group 2 - Tongrentang Medical is a traditional Chinese medicine healthcare group providing comprehensive medical services to individual clients and standardized management services to institutional clients, along with various pharmaceutical and other products [5] - As of the latest feasible date, Tongrentang Medical has established a tiered medical service network, including 12 self-owned offline medical institutions and one internet hospital, as well as 10 offline managed medical institutions [5] - By 2024, Tongrentang Medical is the largest non-public traditional Chinese medicine hospital group in China, holding a market share of 1.7% in terms of total outpatient and inpatient visits [5] - In terms of total medical service revenue for 2024, Tongrentang Medical accounts for 46.5% of the total market size of the traditional Chinese medicine healthcare service industry in China [5] - The company's revenue primarily comes from medical services, management services, and sales of health products and other products, with medical services generating approximately 995 million yuan, management services about 9.6 million yuan, and health product sales around 138 million yuan for the fiscal year 2023 [5] - The company's revenue for the fiscal years 2022, 2023, and 2024 was approximately 911 million yuan, 1.153 billion yuan, and 1.175 billion yuan respectively, with net profits of -9.233 million yuan, 42.634 million yuan, and 46.197 million yuan during the same periods [5]

智通财经APP获悉，据港交所6月30日披露，北京同仁堂医养投资股份有限公司(简称：同仁堂医养)向港 交所主板递交上市申请，中信证券为其独家保荐人。该公司曾于2024年6月28日及12月31日递表港交 所。 截至2025年6月24日，公司已建立分级医疗服务网络，包括12家自有线下医疗机构及一家互联网医院， 以及10家线下管理医疗机构。公司依托知名品牌"同仁堂"及优质的药品，已积累及整合大量线上线下医 疗资源。 按2024年总门诊人次及住院人次计，公司是中国非公立中医院医疗服务行业中最大的中医院集团，市场 份额为1.7%。按2024年医疗服务总收入计，公司以0.2%的市场份额在非公立中医院医疗服务行业中排 名第二，其市场规模占同年中国中医医疗服务行业市场总规模的46.5%。 公司收入主要来自医疗服务；管理服务；及销售健康产品及其他产品。具体来看，截至2023年度，公司 医疗服务产生的收入约9.95亿元，管理服务产生的收入约960万元，销售健康产品及其他产品产生的收 入约1.38亿元。 作为一家中医医疗集团，公司一直利用其在管理能力及医疗资源方面的优势，通过建立、划转及收购以 发展医疗服务网络。于往绩记录期间已并入 ...